Who founded NOVELLUS?

NOVELLUS was founded by Matthew Angel, Christopher Rohde in 2014.

Who are NOVELLUS's investors?

NOVELLUS's investors include Thirdstream Partners.

How much funding has NOVELLUS raised?

NOVELLUS has disclosed $3M raised across 3 rounds.

Where is NOVELLUS headquartered?

NOVELLUS is headquartered in Cambridge, US.

NOVELLUS

Cambridge, US · Founded 2014 · Delaware LLC · 1 known investors

Novellus operates a technology platform for securities lending that lets institutional participants transact directly on a principal-to-principal basis, covering the full lifecycle including settlement and collateralization. It targets institutional market participants looking to in-source securities lending workflows.

Biotech Enterprise Software Fintech SaaS

Founders & leadership

NOVELLUS was founded in 2014 by Matthew Angel and Christopher Rohde.

Matthew AngelManager

Christopher RohdeManager

Huin

Investors · 1

Thirdstream PartnersSan Mateo

Reported raises · per SEC filings

Form D private placements

$3M disclosed across 3 rounds · 2016–2018

▶$1MraisedMar 2018 · 1 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Christopher RohdeExecutive Officer, Director
Matthew AngelDirector

Offering amount: $4M
Amount sold: $1M
First sale: Mar 2018
Incorporated: Limited Liability Company, Delaware, 2014
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$1MraisedFeb 2017 · 1 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Matthew AngelDirector
Christopher RohdeExecutive Officer, Director

Offering amount: $4M
Amount sold: $1M
First sale: Feb 2017
Incorporated: Limited Liability Company, Delaware, 2014
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$1MraisedOct 2016 · 1 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Matthew AngelDirector
Christopher RohdeDirector

Offering amount: $2.5M
Amount sold: $1M
First sale: Oct 2016
Incorporated: Limited Liability Company, Delaware, 2014
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

Noleus Technologies6 shared keywordsNoleus Technologies develops medical device technologies to reduce post-surgical swelling and tissue fluid overload that delay patient recovery. The company's lead product targets post-operative ileus to accelerate bowel function restoration after abdominal surgery.

Companies competing with NOVELLUS for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does NOVELLUS do?: Novellus operates a technology platform for securities lending that lets institutional participants transact directly on a principal-to-principal basis, covering the full lifecycle including settlement and collateralization. It targets institutional market participants looking to in-source securities lending workflows.
Who founded NOVELLUS?: NOVELLUS was founded by Matthew Angel, Christopher Rohde in 2014.
Who are NOVELLUS's investors?: NOVELLUS's investors include Thirdstream Partners.
How much funding has NOVELLUS raised?: NOVELLUS has disclosed $3M raised across 3 rounds.
Where is NOVELLUS headquartered?: NOVELLUS is headquartered in Cambridge, US.